Androgen-withdrawal-induced apoptosis (AWIA) is deregulated in androgen refractory prostate cancer. Androgens have been shown to positively regulate expression of the antiapoptotic FADD-like interleukin-1b-converting enzyme (FLICE)-like inhibitory protein (FLIP), and reduced FLIP expression precedes apoptosis after androgen withdrawal. Here, we show that FLIP protein expression is downregulated in castrated rats, while in LNCaP cells, androgens regulate FLIP in a manner that is dependent on phosphoinositol-3-kinase (PI3K) and Akt signaling. Specifically, treatment of LNCaP cells with LY294002, or expression of either PTEN or a nonphosphorylatable form of FOXO3a (FOXO3aTM), downregulates FLIP protein and mRNA. Conversely, treatment with androgens in the absence of PI3/Akt signaling, or following expression of FOXO3aTM, leads to increased FLIP expression. A FOXO3a binding site was identified in the FLIP promoter and shown necessary for the combined effects of androgens and FOXO3a on FLIP transcription. FOXO3a binds the androgen receptor, suggesting that the transcriptional synergy depends on an interaction between these proteins. Finally, LNCaP cells are sensitized to TRAIL-induced apoptosis by PTEN or LY294002, and rescued by androgens. FOXO3aTM also sensitizes cells to androgen-inhibited TRAIL apoptosis. Androgen rescue was diminished when either FOXO3a or FLIP was reduced by siRNA. These data support a role for FOXO3a in AWIA.
Introduction
Prostate cancer is the third leading cause of cancer death in US men (Jemal et al., 2006) . Most deaths are due to tumors that resist androgen deprivation (Daskivich and Oh, 2006) , the only effective therapy for metastatic disease. Androgen-withdrawal-induced apoptosis (AWIA) is a well-defined physiological event responsible for prostate homeostasis. Molecular mechanisms governing AWIA are likely deregulated in androgenindependent prostate cancers (Kyprianou and Isaacs, 1988) . Thus, investigating AWIA may identify novel targets for therapy.
Signaling pathways mediated by phosphoinositol-3-kinase (PI3K), Akt and PTEN control proliferation and apoptosis. Alterations in the corresponding genes have been linked to prostate cancer in mice and humans (Majumder and Sellers, 2005) . In particular, prostatespecific PTEN deletion induces cancer in mice, and loss of PTEN expression, or inactivating mutation, is detected in most late-stage human cancers. Moreover, PTEN loss correlates with progression to androgen independence (Bertram et al., 2006) . PTEN loss constitutively activates PI3K/Akt signaling and protects cells from apoptotic stimuli. Akt mediates its effects via cell cycle and apoptosis regulating proteins (Cully et al., 2006) . For example, Forkhead transcription factor class-O family (FOXO) members are sequestered in the cytoplasm after phosphorylation by Akt (Brunet et al., 1999) . In the absence of Akt kinase activity, FOXOs localize to the nucleus and stimulate transcription. Androgens negatively regulate the pro-apoptotic effects of constitutively active (non-phosphorylated) FOXOs (Li et al., 2003; Huang et al., 2004) , and FOXO3a activity is reduced in androgen-independent LNCaPs (Lynch et al., 2005 ). Importantly, high-level Akt activation in PTEN-null LNCaPs protects against tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apoptosis (Nesterov et al., 2001) . In contrast, normal prostate epithelial cells are sensitive to TRAIL apoptosis (Nesterov et al., 2002) .
Sensitivity to death-receptor-mediated apoptosis is regulated by the FLICE-like inhibitory protein (FLIP), a proteolytically inactive homologue of caspase-8 (Roth and Reed, 2004) . FLIP regulation by androgens has been demonstrated in our previous in vivo studies (Nastiuk et al., 2003) and in vitro by others (Gao et al., 2005) . Moreover, FLIP overexpression correlates with progression to androgen independence (Gao et al., 2005) . FLIP is regulated by PI3K/Akt signaling (Panka et al., 2001) and in endothelial cells, FLIP is negatively regulated by FOXO3a (Skurk et al., 2004) . Downregulation of FLIP sensitizes prostate cancer cells to TRAIL apoptosis (Zhang et al., 2004) . On the basis of these reports, we investigated the hypothesis that FLIP expression and TRAIL apoptosis are coordinately regulated by the androgen receptor (AR) and FOXO3a.
Results

Androgens differentially regulate FLIP protein levels in normal and neoplastic prostate
We have demonstrated previously that, after castration, FLIP mRNA declines in prostate in advance of the involution and apoptosis of the gland, suggesting that FLIP contributes to AWIA regulation (Nastiuk et al., 2003) . To determine if FLIP protein also declines during AWIA, protein was extracted from the prostates of intact rats or rats castrated 24 h earlier. FLIP was recovered from the extracts (see Materials and methods) before immunoblotting with anti-FLIP (Figure 1 ). The 55 kDa FLIP L protein, as well as smaller amounts of the 43 kDa caspase-8 cleavage product of FLIP, was detected in intact rats but not in castrated rats. There is no nucleosomal fragmentation or involution of rat prostate 24 h after castration, whereas it is clearly evident by 44-52 h (Nastiuk et al., 2003) , indicating that FLIP protein declines before the onset of apoptosis.
Next, androgen regulation of FLIP was examined in PTEN-deficient LNCaP prostate cancer cells. Cells were incubated for 24 h in media containing androgendepleted charcoal-dextran-stripped serum (CDS) and treated with the synthetic androgen R1881. Prostatespecific antigen increased but, unexpectedly, FLIP was downregulated at 24 h (Supplementary Figure S1a) , indicating that FLIP is oppositely regulated in transformed human prostate epithelial cells compared to rat prostate glands. A time course (Supplementary Figure  S1b) showed a 50% decline in FLIP protein 24 h after R1881 treatment. Phospho-Akt levels were unaffected by R1881 (Supplementary Figure S1b) .
Androgens upregulate FLIP after PI3K inhibition FLIP levels decline in many cell lines after inhibition of PI3K/Akt signaling (Panka et al., 2001) . When LNCaP cells were treated with the PI3K inhibitor LY294002 in the absence of androgens, FLIP levels decreased (Supplementary Figure S2a) concurrent with a decline in phospho-Akt. This decrease begins 2 h after LY294002 addition (Supplementary Figure S2b) . As androgens protect against apoptosis induced by PI3K inhibition (Kimura et al., 2001) and as FLIP inhibits death receptor-ligand-induced apoptosis, we tested the effects of androgens on FLIP expression when PI3K/ Akt signaling is repressed. LNCaP cells were grown in varying concentrations of R1881 and treated with LY294002 for an additional 24 h. FLIP protein was upregulated in increasing concentrations of R1881 only when PI3K was inhibited (Figure 2a ). Prostate-specific antigen levels increased in response to R1881 even in the presence of LY294002. Although a decrease in phosphoAkt was detected in response to R1881 in this experiment, this was not seen reproducibly (for example, Supplementary Figure S1b) . The effect of androgens on FLIP protein expression was mirrored at the mRNA level as measured by quantitative reverse transcription-PCR (RT-PCR) (Figure 2b ). Specifically, FLIP L mRNA increased after androgen treatment when PI3K was inhibited.
Androgen induction of FLIP transcription requires a Forkhead binding site in the FLIP promoter To distinguish among mechanisms for mRNA regulation, we analysed the FLIP promoter. A search (Matys et al., 2003) identified a Forkhead consensus binding site (TGTTTAC) at À65 to À58, whereas a previous report (Gao et al., 2005) identified androgen response elements within exon 1. Constructs containing portions of the FLIP promoter upstream of a luciferase reporter were made to investigate the Forkhead binding site (Figure 3a) . When LNCaPs were transfected with these reporters, relatively little luciferase activity was detected whether cells received androgens or not (Figure 3b , left half). However, when the À212 to þ 250 reporter was co-transfected with a cDNA encoding constitutively active FOXO3a (FOXO3aTM), luciferase activity was detected in the absence of androgens and a significant induction was observed on R1881 addition (Figure 3b , right half). FOXO3aTM is mutated at three Akt phosphorylation sites and thus localizes to the nucleus even in the presence of constitutive Akt. Androgen induction was largely eliminated when reporters lacked the Forkhead element (due to deletion or mutation; Figure 3b ). To confirm that FOXO3a regulates FLIP in Figure 1 FLIP L protein is downregulated in rat prostate after castration. Prostates were harvested from two untreated adult male rats (normal; lanes 2-3) or from three rats 24 h after castration (castrate; lanes 4-6). Tissue was homogenized, FLIP protein affinity precipitated using maltose binding protein (MBP)-linked DED fusion proteins and the resulting complexes were immunoblotted and probed with anti-rat FLIP antibody (G878) (see Materials and methods). Lane 1 is HEK293T cells overexpressing rat FLIP L . About 3% of each tissue homogenate used in the affinity precipitation was immunoblotted with anti-b-actin.
response to androgens, a dominant-negative FOXO3aTM was constructed by deleting the transactivation domain (Skurk et al., 2004) . This construct inhibited the inductive effects of full-length FOXO3aTM (Figure 3c , middle column). A DNA binding mutant (FOXO3aTM-H215R) was a significantly weaker inducer of FLIP transcription in response to androgens (Figure 3c , right side). Thus, androgens and FOXO3a synergistically activate FLIP transcription via a newly identified Forkhead element.
To confirm the effects in Figure 3b , and to examine the role of prostate epithelial cell-specific proteins (such as AR-specific co-activators) on FLIP transcription, we repeated the reporter assays in HEK293T cells. Although derived from embryonic kidneys, these cells express neurofilaments, indicating neuronal origin (Shaw et al., 2002) . FOXO3aTM was transfected with or without AR, cells were treated with R1881 and transcriptional activity was measured from either the wild-type FLIP luciferase reporter or the reporter with mutations in the Forkhead element ( Figure 3a ). Both AR and FOXO3aTM stimulated FLIP reporter activity ( Figure 3d ). However, FOXO3aTM-in the presence of androgen signaling and an intact Forkhead elementproduced substantially greater activity, confirming that these transcription factors synergistically activate FLIP transcription, even in the absence of prostate-specific factors (Figure 3d , far right columns). Mutation of the Forkhead element reduced but did not eliminate activity, similar to Figure 3a . Interestingly, AR and FOXO3aTM synergized, although to a lesser extent, in the absence of added androgens. Although others have shown that FOXO1a can bind AR (Li et al., 2003) , it has a much weaker effect on FLIP reporter activity (Figure 3e After 24 h, the media was changed to 10% charcoal-dextranstripped serum (CDS) for 24 h followed by the addition of R1881, 20 mM LY294002 and/or vehicle for an additional 24 h, as indicated. Cells were then harvested and lysates immunoblotted with indicated antibodies. Ethanol (0.1%) was used as the vehicle control in lane 1. Results are representative of three independent experiments. (b) FLIP mRNA regulation. RNA was extracted from LNCaP cells treated as in panel a and reverse-transcribed cDNA was used to determine the FLIP L mRNA copy number by quantitative reverse transcription PCR (RT-PCR) (see Materials and methods). FLIP L levels were normalized to the vehicle control sample in the column at the far left to obtain the fold change in mRNA levels for each treatment condition. RNA from four independent experiments was reverse transcribed and PCR was performed on cDNA prepared in triplicate for each experiment. **P-values for 0 versus 10 nM R1881 were o0.01 for culture receiving DMSO. *P-values for 0 versus 10 nM R1881 were o0.05 for cultures receiving LY2945002. Figure S2 ).
FOXO3a binds the AR
As FOXO1a binds the AR (Li et al., 2003) , we hypothesized that FOXO3a would also, as part of the mechanism of synergistic transactivation of the FLIP promoter. To test this, FLAG-tagged FOXO constructs were co-expressed with AR in HEK293T cells. Protein complexes were immunoprecipitated with anti-FLAG antibody, in the presence or absence of R1881, and immunoblotted with anti-AR antibodies. As expected (Li et al., 2003) , the AR co-immunoprecipitated FOXO1a (Figure 5a ). The pattern of association for FOXO3a is very similar. The AR co-immunoprecipitates both wild-type and triple-mutant FOXO3a, and the complexes were present in both cytoplasmic and nuclear compartments (Figure 5b) . The FOXO3a-AR interaction was androgen dependent in both cytoplasmic and nuclear extracts. In both Figures 5a and b , the level of cytoplasmic AR is increased in cells treated with androgen, consistent with reports that ligand stabilizes AR levels (Furutani et al., 2002; Li et al., 2003) .
Androgens rescue TRAIL-induced apoptosis in LNCaP cells expressing PTEN or FOXO3aTM
To determine if FLIP regulation is physiologically relevant, we investigated TRAIL-induced apoptosis. LNCaP cells, cultured in the presence or absence of R1881 and LY294002, were treated with TRAIL and assayed for apoptosis (see Materials and methods). When PI3K signaling was inhibited by LY294002, TRAIL induced cell death ( Figure 6 , left side). Exposure to R1881 partially rescued cells from apoptosis ( Figure 6 , right side), consistent with our findings that androgens increased the level of the antiapoptotic FLIP protein under the same conditions (Figure 2 ). As expression of PTEN or FOXO3aTM mimics the effects of LY294002 on FLIP expression, we hypothesized that transfection of these cDNAs should also sensitize cells to TRAIL apoptosis. Androgen treatment in the presence of reduced Akt signaling, by increasing FLIP, should then rescue transfected cells from apoptosis. Indeed, restoring PTEN expression by transfection leads to significant apoptosis even in the absence of TRAIL (Figure 7b , far left). Apoptosis was further enhanced by TRAIL, but prevented when R1881 was added before TRAIL (Figure 7b , dark gray bars). This is visualized in plots from the fluorescence-activated cell sorting (FACS) analysis (Figure 7a) . In PTEN-transfected cells, there is a significant shift of the population from the lower left quadrant (live cells, not staining with either Annexin-V or 7-AAD (7-aminoactinomycin D)) to the lower right quadrant (apoptotic cells staining with Annexin V) after TRAIL addition. R1881 prevents this shift. FOXO3aTM also induced TRAIL sensitivity, which could be partially rescued by R1881 (Figure 7b , light gray bars). FACS plots in Figure 7a demonstrate the appearance of apoptotic cells in the lower right quadrant of TRAIL-treated cells and a corresponding reduction when R1881 is added.
Reduced FLIP or FOXO3a inhibits androgen rescue of TRAIL-induced apoptosis
To confirm the physiological relevance of FLIP transcriptional regulation during TRAIL-induced apoptosis of LNCaP cells, we used siRNA to knock down endogenous FLIP and FOXO3a proteins (Figures 8c  and f) , and then analysed the transfected cells for TRAIL-induced apoptosis, following the protocol in Figure 6 . R1881-mediated rescue from TRAIL-induced apoptosis was suppressed in cells with reduced FLIP expression (Figures 8a and b) . In Figure 8c , the reduction of FLIP is, in some cases, due to both siRNA knockdown and TRAIL effects. TRAIL induces cleavage of the 55 kDa full-length FLIP L protein to form a 43 kDa protein that is still active in repressing caspase-8 activity (Krueger et al., 2001 ) Thus, the 43 kDa FLIP protein in Figure 8 
Discussion
Androgens are necessary for prostate maintenance, as demonstrated by AWIA of luminal secretory epithelium after castration (Kyprianou and Isaacs, 1988) . Transforming growth factorb plays a key role in AWIA (Martikainen et al., 1990 ) and caspase-3 activation has been implicated (Marti et al., 1999) , but the role of death Figure 4 . After transfection, cultures were divided into four parts and treated for 18 h with TRAIL (100 ng/ml), and/or R1881 (1 nM), or left untreated in media containing 10% charcoal-dextran-stripped serum (CDS) (CDS) as indicated along the left side of the panel. Staining and FACS analysis was as in Figure 6 . (b) Quantitation of live cell fraction determined from FACS plots. The percentage of live cells (Annexin V-and 7-AAD-negative cells; lower left quadrants) is shown for each of the treatment conditions and constructs introduced into the cells. Each data point represents two separate experiments conducted in triplicate. The **P-value derived by comparing the indicated pair of columns was o0.01, or y P-value derived by comparing the indicated pair of columns was o0.1.
receptors such as Fas remains uncertain (Suzuki et al., 1996; de la Taille et al., 1999; Sugihara et al., 2001) . Our previous studies demonstrated that mRNA levels of FLIP, a catalytically inactive caspase-8 homologue that negatively regulates death receptors, declined before the onset of castration-induced apoptosis (Nastiuk et al., 
2003
). This suggests that FLIP is an androgen-regulated gene controlling AWIA. Subsequently, LNCaP cells expressing FLIP were reported to form androgenindependent tumors at a higher rate than parental cells (Gao et al., 2005) . LNCaP-derived tumors overexpressing the caspase-8 inhibitor crmA behaved similarly (Srikanth and Kraft, 1998) . Also, FLIP levels were elevated in androgen-independent human cancers (Gao et al., 2006) , supporting the hypothesis that FLIP inhibits caspase-8 to regulate AWIA in normal and neoplastic prostate.
In the first part of this paper, we demonstrate that FLIP is regulated by androgens in vitro in a manner resembling its regulation in vivo, and we characterize the molecular mechanisms regulating FLIP expression. Figure 1 confirmed that, as observed for FLIP mRNA (Nastiuk et al., 2003) , FLIP protein declined in normal rat prostate 24 h after castration, but before the appearance of any significant evidence of apoptosis (Nastiuk et al., 2003) . Immunohistochemical staining of prostate glands from castrated mice demonstrated a temporally similar pattern of FLIP expression (Gao et al., 2006) . The timing of FLIP protein modulation suggests that downregulation either facilitates the apoptotic effects of a preexisting death ligand or occurs coordinately with the upregulation of a death ligand(s).
To further characterize androgen regulation of FLIP expression, we used the human prostate cancer line LNCaP as an in vitro model. LNCaP has a deletion of one PTEN allele (Hermans et al., 2004 ) and a frameshift mutation in the other (Li et al., 1997) , producing constitutive PI3K/Akt signaling, which likely drives survival and proliferation. FLIP inhibits death receptordriven apoptosis and therefore promotes survival. Moreover, constitutive PI3K/Akt signaling increases FLIP in the androgen-independent prostate cancer lines PC3 and DU145 (Panka et al., 2001 ). Our data demonstrate that in androgen-responsive LNCaPs, treatment with a PI3K inhibitor decreases FLIP protein (Supplementary Figure S2) and mRNA (Figure 2b) . Similarly, re-introduction of PTEN decreased FLIP protein (Figure 4c ) and mRNA (Figure 4d ). When we examined the effects of androgens on FLIP expression in the constitutive Akt signaling state seen in LNCaP cells (Figure 2) , FLIP was downregulated, the opposite of the response in normal rat prostate (Figure 1) . However, when PI3K was inhibited (Figure 2) or Akt signaling was inhibited with PTEN (Figure 4) , androgens upregulated FLIP expression, as in normal rat prostate. The levels of phospho-Akt are low or undetectable in most samples of benign human prostate epithelium (Liao et al., 2003; Ayala et al., 2004) . Thus, when Akt signaling activity in LNCaPs is reduced to resemble the level in normal epithelium, FLIP is positively regulated by androgens, consistent with a possible role in AWIA. Gao et al. (2005) also demonstrated that androgens upregulate FLIP in LNCaP, but in contrast to our data, the effects apparently did not require inhibition of PI3K/Akt signaling. These authors demonstrated androgen-dependent upregulation of FLIP mRNA, but did not examine FLIP protein. They also identified the androgen-responsive elements within exon I (Figure 3a) , although this data are mainly derived from reporter gene studies in PC3 cells.
Our identification of a Forkhead box element within the FLIP upstream regulatory region (Figure 3a) suggests that a FOXO transcription factor might mediate Akt signaling effects. Indeed, Figures 3 and 4 indicate that FOXO3a is a primary mediator of PI3K signaling on FLIP expression, and demonstrate a strong effect at the transcriptional level via FOXO3a binding to the FLIP promoter. In addition, we show that FOXO3a can bind the AR (Figure 5b) , providing a plausible mechanism for the observation that FOXO3a cooperates with AR to regulate FLIP transcription. FOXO1a has also been implicated in AR-driven survival of prostate cell lines (Li et al., 2003) . However, although FOXO1a binds AR (Figure 5a ) and stimulates transcription from a Forkhead element (Figure 3e) , it is much weaker in cooperating with AR to activate the FLIP promoter (Figure 3e ). This indicates that synergy between AR and FOXO3a is specific. Moreover, our results agree with a report that FOXO3a downregulates FLIP in endothelial cells (Skurk et al., 2004) . The ability of FOXO3a and AR to bind (Figure 5b ) and synergistically activate FLIP transcription in HEK293T cells (Figure 3d ) indicates that this mechanism is not strictly reliant on prostate-specific proteins, such as transcriptional co-activators.
Androgens have been shown to inhibit PTEN-or FOXO1a-induced apoptosis of prostate cancer cells (Li et al., 2001 (Li et al., , 2003 Huang et al., 2004) , while PTEN expression was shown to sensitize LNCaPs to TRAIL (Yuan and Whang, 2002) . Consistent with FLIP regulation of death receptor-mediated apoptosis and our observations on FLIP expression described above, we observed that LY294002 treatment (Figure 6 ), or PTEN/FOXO3aTM expression (Figure 7) , sensitized LNCaPs to TRAIL apoptosis and, furthermore, that androgen treatment rescued this effect. Knockdown of FLIP or FOXO3a inhibited androgen-mediated rescue of TRAIL-mediated apoptosis (Figure 8 ), providing further support for a functional role for FOXO3a regulation of FLIP transcription in the presence of androgens. Androgens may play a protective role by synergistically upregulating FLIP expression in a manner that is dependent on active FOXO3a. The FACS data in Figure 7 indicate that FOXO3aTM accounts only for a portion of the PTEN-sensitizing effect on TRAIL-mediated apoptosis. Similarly, depletion of FLIP and FOXO3a only partially blocks androgen-driven rescue from TRAIL induced death (Figure 8 ). Thus, it is likely that other pro-apoptotic, PTEN-driven events account for the remainder of the effect (Majumder and Sellers, 2005) . Finally, our findings that PI3K/Akt signaling, via FOXO3a, modulates androgen regulation of FLIP might provide insight into the process of prostate carcinogenesis. Specifically, androgen deprivation may be ineffective in downregulating FLIP in prostate tumor cell subpopulations lacking PTEN, thereby favoring the survival or growth of these cells. This may help account for the predominant PTEN-negative status of androgenindependent tumors.
Materials and methods
Cell lines
Details describing the culture of HEK293T and LNCaP cells are provided in the Supplementary Information.
Plasmid constructs
The À212 to þ 250 bp FLIP promoter was PCR amplified from BAC clone RP11-536I18 (CHORI, Oakland, CA, USA) and inserted into the KpnI and XhoI sites of pGL3 Basic (Promega, Madison, WI, USA). A deletion construct of this promoter fragment was made using the MluI site at À52. Overlap PCR was used to mutate the Forkhead transcription factor binding site at À65 to À58 from TGTTTAC to TGgaaAC. N-terminal FLAG-tagged FOXO3a constructs were made by subcloning a cDNA encoding the either the wild-type or triple FOXO3a mutant (T32A/S253A/S315A; M Greenberg, Harvard Medical School, Boston, MA, USA), into pFLAG-CMV2 (Sigma, St Louis, MO, USA). A dominantnegative FOXO3aTM construct was made by deleting the transactivation domain as previously reported (Skurk et al., 2004) , and a plasmid encoding FLAG-FOXO3aTM-H215R was prepared by restriction fragment cloning from pECEFOXO3aTM-H215R (D Fruman, University of CA, Irvine, CA, USA) into pFLAG-CMV2. The plasmid pMT2T-PTEN-HA, encoding a C-terminal-tagged protein, was made by PCR cloning full-length human PTEN into pMT2T-HA. FOXO1a constructs (Tang et al., 1999) were from K Guan (University of Michigan, Ann Arbor, MI, USA). A plasmid encoding a fusion between MBP (maltose binding protein) and the rat caspase-8 DEDs (residues 1-181) was prepared by Pfu PCR amplification of the caspase-8 DED and cloning into the pMAL-2c vector (New England Biolabs, Ipswich, MA, USA). A plasmid encoding the human AR (pCMhAR) was obtained from R Miesfeld (University of Arizona, Tucson, AZ, USA). All PCR-generated constructs were sequenced.
Immunoblotting Post-nuclear (cytoplasmic) extracts were prepared by lysing cells in NP40 lysis buffer (1% NP40, 1 mM NaVO 4 , 100 mM NaF, 2.5 mM ZnCl 2 , 10% glycerol, 0.2 mM phenylmethylsulfonylfluoride (PMSF) and protease inhibitor cocktail (Sigma) in Tris-buffered saline solution). Whole-cell lysates were prepared by lysing cells in sodium dodecyl sulfate sample buffer (62.5 mM Tris-HCl (pH 6.8), 10% glycerol, 2% sodium dodecyl sulfate, 0.01% bromophenol Blue, 5% 2-mercaptoethanol) followed by sonication.
Mature Sprague-Dawley rats (B350 g) were castrated under methoxyflurane anesthesia and 24 h later killed, and the ventral lobe of the prostate was snap-frozen. Tissue was pulverized and protein extracted from individual prostates using 10 volumes of the lysis buffer described above, plus zVAD-Fmk (5 mM; BIOMOL, Plymouth Meeting, MA, USA). Because we were unable to immunoprecipitate FLIP efficiently, we used the homotypic affinity of DED domains to recover FLIP from rat tissue lysates. Briefly, lysates were sonicated and 750 mg of protein from a 1.5 Â 10 4 g supernatant were pre-cleared with 300 mg of amylose beads. MBP-rat caspase-8 DED fusion protein was coupled to amylose beads with glutaraldehyde. The cleared lysate was incubated for 4 h with 30 mg of coupled MBP-DED protein, and bound protein was immunoblotted. To confirm equal amounts of protein in each affinity precipitation, 50 mg of cleared lysate protein was immunoblotted in parallel with anti-actin.
For co-immunoprecipitation, HEK293T cells were lysed in 20 mM Tris, pH 7.4, 200 mM NaCl, 5 mM EDTA, 12.5% glycerol, 0.2% NP-40, 1 mM dithiothreitol, 0.2 mM PMSF and protease inhibitor cocktail (Sigma), incubated on ice for 10 min and centrifuged at 1.5 Â 10 4 g for 5 min. The resulting supernatant was considered to be cytoplasmic and was removed from the nuclear pellet. The nuclei were lysed in the same buffer by sonication and centrifuged as before to remove insoluble material. Cytoplasmic or nuclear fraction of lysates was incubated with 1 mg polyclonal anti-FLAG antibody (F7425; Sigma) overnight at 4 1C and subsequently with protein A-Sepharose beads for an additional 4 h. Beads were washed, boiled in sodium dodecyl sulfate sample buffer and electrophoresed. Detailed descriptions of immunoblotting steps and antibodies are given in the Supplementary Information.
Quantitative RT-PCR RNA, extracted with TRIzol (Invitrogen, Carlsbad, CA, USA), was reverse transcribed using SuperScript II MMLV reverse transcriptase (Invitrogen) and real-time PCR was performed with SYBER Green (Molecular Probes, Eugene, OR, USA) as described (Nastiuk et al., 2003) . The primer pairs, which spanned at least one intron, are: for FLIP L , 5 0 -AGGAGC AGGGACAAGTTACAGG-3 0 and 5 0 -CTAGGGGCTTGC TCTTCATCTT-3 0 ; and for b-actin, 5 0 -CAGAGCAAGA GAGGCATC-3 0 and 5 0 -CAGAGGCATACAGGGACAG-3 0 . The mRNA copy numbers were determined by comparing the amplification profiles (log fluorescence versus cycle number) of the SYBR Green signal recorded 2 1C below the duplex melting point with serially diluted internal standards of the same target gene. FLIP L copy numbers were normalized to b-actin copy numbers. Each reverse transcription reaction was performed in triplicate and real-time PCR reactions were carried out in triplicate for each sample. Statistical analysis was performed using Student's t-test.
DNA transfection
For Luciferase assays, LNCaP cells (1 Â 10 5 cells) were seeded on 24-well plates 2 days before lipofection (Lipofectamine, Invitrogen) in antibiotic-free RPMI with 10% CDS. Briefly, 100 ng of firefly luciferase reporter construct plus 25 ng of FOXO3a expression construct and 25 ng of constitutive Renilla luciferase reporter were transfected in serum-free RPMI (without phenol red). DNA content was adjusted by the addition of vector. After 3 h, cells were incubated in 1 nM R1881 or vehicle in 10% CDS/RPMI for 24 h. For other analyses, LNCaP cells (2 Â 10 6 cells) were Nucleofected with 2 mg plasmid DNA at the T09 setting in buffer R (Nucleofector II; Amaxa, Gaithersburg, MD, USA). HEK293T cells (6 Â 10 5 cells) were seeded on 6-well plates 18-20 h before calcium phosphate transfection in DMEM (Dulbecco's modified Eagle's medium) with 10% CDS. Briefly, 100 ng of Renilla luciferase reporter plus 750 ng FOXO expression construct plus 750 ng AR plasmid and 400 ng of firefly luciferase reporter were transfected into each well. After 6 h, cells were glycerol shocked, and then media was replaced with DMEM with 10% CDS containing either 1 nM R1881 or vehicle control. For co-immunoprecipitation, HEK293T cells were transiently transfected using calcium phosphate as in the luciferase assays. , 2006) or human FOXO3a (Dharmacon MQ-003007, Lafayette, CO, USA; sequences available on request) was transfected at 6 nM or 4 nM total oligo concentration, using 4 ml Oligofectamine reagent (Invitrogen) per dish. Non-targeting control siRNA (5 0 -GACGA UUACGAACGAUCAA-3 0 ) was transfected at the corresponding concentration of the targeting siRNA. Serum (10% CDS) was added after 4 h.
Reporter gene assays
Cells were harvested, lysed in Passive Lysis Buffer (Promega) and the supernatant was cleared by centrifugation at 1.5 Â 104 g and assayed simultaneously for firefly and Renilla luciferase activity using commercial reagents (Promega). Fold induction was calculated by first normalizing firefly activity by the corresponding Renilla activity. Normalized values were divided by the specified control.
FACS analysis of apoptosis
LNCaP cells (3-5 Â 10 5 cells) were detached from dishes by pipetting and then resuspended in PBS plus 0.25% trypsin for 5 min to disrupt clumped cells. Trypsin was inactivated by the addition of 10% CDS, the cells were washed in HBSS (Hank's balance salt solution) and incubated in 0.1 ml HBSS plus R-phycoerythrin-conjugated Annexin-V (1:100; Invitrogen) and 7-AAD (1:200; Invitrogen) for 15 min at room temperature in the dark. Cells were washed, resuspended in HBSS and analysed by two-color FACS (BD Biosciences, San Jose, CA, USA). Data was analysed using FloJo software (Tree Star). Statistical analysis was performed by Student's t-test.
